Clinical Trials

40 enrolled

Neoplasm Metastasis

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 3 Active not recruiting

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

406 enrolled 18 charts 1 FDA

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04449549 2026-03-09

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

82 enrolled

Neoplasms

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Other hematologic neoplasm

40 enrolled

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT01207492 2026-02-20

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Phase 3 Active not recruiting

17 enrolled 8 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05456191 2026-02-06

ASC4START

568 enrolled

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03874858 2026-01-06

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04626024 2025-12-19

TOKIN

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Other hematologic neoplasm

81 enrolled 20 charts

Leukemia, Myeloid, Chronic-Phase

NCT03784014 2025-12-11

MULTISARC

Phase 3 Active not recruiting

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT03578367 2025-11-10

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

104 enrolled 11 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01316250 2025-10-02

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Phase NA Completed

13 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02201459 2025-10-02

PETALs

Phase 3 Completed

200 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02917720 2025-09-22

NAUT

75 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07138378 2025-08-22

XS003-11

Phase 1 Completed

128 enrolled

Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Neoplasm Metastasis

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

51 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06409936 2025-07-08

PEARL

160 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Phase 1 Completed

11 enrolled 9 charts

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled